The cosmetic peptides are unusual in this field: they are the one class where the research is oldest, the mechanism is best characterised, and the honest summary is still narrower than the marketing.
GHK-Cu — glycyl-L-histidyl-L-lysine complexed with copper — was isolated from human plasma by Loren Pickart in 1973. It is not an exotic compound. It occurs naturally in human tissue, appears in wound fluid, and its plasma concentration is reported to decline substantially with age, from roughly 200 ng/mL in young adults to under 100 ng/mL by the sixties. That decline is the observation the entire field grew out of.
What the research reports
In cell culture, GHK-Cu has been shown to stimulate collagen and glycosaminoglycan synthesis in fibroblasts, and to modulate expression of a broad set of genes involved in tissue remodelling. Pickart's group and others have published extensively on this; it is the most mechanistically detailed peptide story in cosmetic science.
In animal wound models, copper peptide preparations have been reported to accelerate closure and improve the quality of repaired tissue.
In humans, the evidence that exists is topical and cosmetic. Small controlled trials of copper-peptide creams have reported improvements in measures like skin density, fine-line appearance and photodamage over 12-week windows, generally in participant counts in the dozens, frequently with industry sponsorship. That is real evidence for a cosmetic claim, at the scale cosmetic evidence is usually generated.
Where it stops
Two limits matter, and both get skipped in the popular version.
Route. Nearly all human GHK-Cu data concerns topical application to skin. The literature on injected copper peptide in humans is, for practical purposes, absent. Evidence does not transfer across routes: what a molecule does applied to the stratum corneum tells you little about what it does administered systemically, and vice versa.
Endpoint. Cosmetic trials measure appearance — instrument readings of skin roughness, elasticity, investigator scoring, participant self-report. These are legitimate cosmetic endpoints and they are not clinical outcomes. "Improved appearance in a 12-week trial" is a different claim from anything about tissue health, and the papers themselves are careful about the distinction.
The copper question
One detail worth understanding because it explains why the class is formulation-sensitive: GHK's activity is bound up with its copper complex. The peptide is a copper-binding molecule, and much of the proposed mechanism runs through copper delivery and redox chemistry. That makes the complex, not just the peptide sequence, the thing under study — which is why a certificate confirming the peptide's identity answers only part of the question for this compound, and why formulation details matter more here than for a simple sequence.
The honest summary
Best-characterised mechanism in the peptide field. Genuine, if modest, human cosmetic evidence — topical, short-window, appearance endpoints, small samples. Essentially no human data for other routes. A fifty-year research record that supports a specific, narrow claim very well, and does not support the broader ones it gets attached to.
That's a better position than most compounds in this field can claim. It just isn't the position the internet gives it.
Research use only. No compound discussed here is FDA-approved for any indication, and nothing on this page is medical advice.
For research use only · Not for human or veterinary use · No compound discussed here is FDA-approved for any indication